Rapid regression of extensive retinovitreal neovascularization secondary to branch retinal vein occlusion after a single intravitreal injection of bevacizumab

Int Ophthalmol. 2005 Aug-Oct;26(4-5):191-3. doi: 10.1007/s10792-007-9036-y. Epub 2007 Feb 8.

Abstract

Purpose: To report the rapid regression of extensive retinovitreal neovascularization following the administration of a single dose of intravitreal bevacizumab.

Methods: A 60-year-old woman presented with recurrent vitreous hemorrhage originating from active retinovitreal neovascularization secondary to branch retinal vein occlusion. The neovascular tissue remained active despite multiple sessions of laser therapy. Intravitreal injection of 1.25 mg bevacizumab was performed.

Results: Rapid regression of the retinovitreal neovascularization, a marked reduction in retinal vein engorgement, and visual improvement was observed 1 week after the intervention

Conclusion: Intravitreal bevacizumab can result in the rapid and dramatic regression of retinovitreal neovascularization refractory to previous laser photocoagulation.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Disease Progression
  • Female
  • Fluorescein Angiography
  • Follow-Up Studies
  • Fundus Oculi
  • Humans
  • Injections
  • Middle Aged
  • Retinal Neovascularization / drug therapy*
  • Retinal Neovascularization / etiology
  • Retinal Vein Occlusion / complications*
  • Retinal Vein Occlusion / pathology
  • Tomography, Optical Coherence
  • Vascular Endothelial Growth Factor A
  • Vitreous Body / blood supply*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab